Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 4/20 | 0.49 |
| ▸ | P2RX2 | Q9UBL9 | 4/20 | 0.49 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.45 |
| ▸ | DHODH | Q02127 | 1/20 | 0.42 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | RXRB | P28702 | 1/20 | 0.39 |
| ▸ | FABP1 | P07148 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL311079 | 0.79 | P2RX3 (0.53) | P2RX3P2RX2 | |
| SCHEMBL16542508 | 0.77 | ALDH1A1 (0.54) | KMT2ASMN1; SMN2 | |
| SCHEMBL2174227 | 0.76 | ALDH1A1 (0.57) | P2RY14DHODHKMT2ALMNAHTT | |
| SCHEMBL14687147 | 0.76 | CA12 (0.53) | KMT2AABL1 | |
| SCHEMBL2761075 | 0.76 | DHODH (0.50) | P2RY14DHODHRXRARXRBFABP1 | |
| SCHEMBL16418266 | 0.76 | DHODH (0.50) | P2RY14DHODHRXRARXRBFABP1 | |
| SCHEMBL13002224 | 0.75 | P2RX3 (0.68) | P2RX3P2RX2ABL1 | |
| SCHEMBL4636834 | 0.75 | GAA (0.46) | KMT2ALMNAABL1 | |
| SCHEMBL2173190 | 0.74 | ALDH1A1 (0.54) | P2RY14DHODHKMT2ALMNAHTT | |
| SCHEMBL2709019 | 0.72 | P2RX3 (0.74) | P2RX3P2RX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170056398-A1 | SUBSTITUTED PYRIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2017-03-02 | — | — | US | claimed |
| EP-2445889-A1 | NOVEL OXAZOLONE AND PYRROLIDINONE-SUBSTITUTED ARYLAMIDES | F. Hoffmann-La Roche AG (CH) | 2012-05-02 | — | — | EP | claimed |
| WO-2010149541-A1 | NOVEL OXAZOLONE AND PYRROLIDINONE-SUBSTITUTED ARYLAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-12-29 | — | — | WO | claimed |
| US-20100324069-A1 | OXAZOLONE AND PYRROLIDINONE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | CHEN LI | 2010-12-23 | — | — | US | claimed |
| US-20170056398-A1 | SUBSTITUTED PYRIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2017-03-02 | — | — | US | disclosed |
| US-9512112-B2 | Substituted pyridines as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2016-12-06 | — | — | US | disclosed |
| US-20140323499-A1 | OXAZOLONE AND PYRROLIDINONE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2014-10-30 | — | — | US | disclosed |
| US-8809402-B2 | Oxazolone and pyrrolidinone-substituted biphenyls as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2014-08-19 | — | — | US | disclosed |
| EP-2445889-A1 | NOVEL OXAZOLONE AND PYRROLIDINONE-SUBSTITUTED ARYLAMIDES | F. Hoffmann-La Roche AG (CH) | 2012-05-02 | — | — | EP | disclosed |
| WO-2010149541-A1 | NOVEL OXAZOLONE AND PYRROLIDINONE-SUBSTITUTED ARYLAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-12-29 | — | — | WO | disclosed |
| US-20100324069-A1 | OXAZOLONE AND PYRROLIDINONE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | CHEN LI | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323499-A1 | OXAZOLONE AND PYRROLIDINONE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX2, P2RX1 | P2RX3 1/4885P2RX2 2/4885P2RY14 17/4885 |
| US-20100324069-A1 | OXAZOLONE AND PYRROLIDINONE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX2, P2RX1 | P2RX3 1/4885P2RX2 2/4885P2RY14 17/4885 |
| US-20170056398-A1 | SUBSTITUTED PYRIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX2, P2RX7 | P2RX3 1/4885P2RX2 2/4885P2RY14 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.